Atreides Management LP Acquires New Stake in Natera, Inc. $NTRA

Key Points

• Atreides Management acquired 104,385 Natera shares worth approximately $28.3 million, giving it about a 0.07% stake. Institutional investors collectively own 99.9% of Natera’s stock.
• Natera reported stronger-than-expected quarterly results, with revenue rising 37.7% year over year to $752.75 million and an adjusted loss of $0.47 per share, beating estimates by $0.02.
• Analyst sentiment remains favorable, with a consensus “Moderate Buy” rating and an average price target of $319.38, although the stock opened at $338.45—near its 52-week high of $340.96.

Atreides Management LP acquired a new stake in Natera, Inc. (NASDAQ:NTRA - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 104,385 shares of the medical research company's stock, valued at approximately $28,335,000. Atreides Management LP owned about 0.07% of Natera as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Horizon Investments LLC boosted its stake in shares of Natera by 22.0% during the fourth quarter. Horizon Investments LLC now owns 244 shares of the medical research company's stock valued at $56,000 after purchasing an additional 44 shares during the period. Parallel Advisors LLC increased its stake in Natera by 5.5% in the 1st quarter. Parallel Advisors LLC now owns 905 shares of the medical research company's stock worth $181,000 after buying an additional 47 shares during the period. First Horizon Corp increased its stake in Natera by 5.5% in the 1st quarter. First Horizon Corp now owns 982 shares of the medical research company's stock worth $196,000 after buying an additional 51 shares during the period. Siemens Fonds Invest GmbH lifted its holdings in Natera by 3.1% during the 3rd quarter. Siemens Fonds Invest GmbH now owns 1,804 shares of the medical research company's stock valued at $290,000 after buying an additional 54 shares in the last quarter. Finally, Alamea Verwaltungs GmbH lifted its holdings in Natera by 2.9% during the 4th quarter. Alamea Verwaltungs GmbH now owns 2,229 shares of the medical research company's stock valued at $515,000 after buying an additional 62 shares in the last quarter. Hedge funds and other institutional investors own 99.90% of the company's stock.

Natera Stock Performance

NASDAQ NTRA opened at $338.45 on Thursday. The company has a market cap of $48.78 billion, a PE ratio of -248.86 and a beta of 1.51. The firm's 50 day moving average price is $281.03 and its 200-day moving average price is $232.01. Natera, Inc. has a 52-week low of $157.43 and a 52-week high of $340.96.

Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The medical research company reported ($0.47) EPS for the quarter, topping analysts' consensus estimates of ($0.49) by $0.02. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The company had revenue of $752.75 million during the quarter, compared to the consensus estimate of $661.24 million. During the same quarter in the previous year, the firm posted ($0.74) earnings per share. Natera's revenue for the quarter was up 37.7% compared to the same quarter last year. On average, analysts forecast that Natera, Inc. will post -1.02 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Piper Sandler upped their target price on shares of Natera from $249.00 to $363.50 and gave the stock an "overweight" rating in a research note on Wednesday, August 12th. Stephens lifted their price target on shares of Natera from $305.00 to $350.00 and gave the company an "overweight" rating in a research note on Wednesday, August 12th. BTIG Research boosted their price target on Natera from $290.00 to $320.00 and gave the company a "buy" rating in a report on Friday, August 7th. The Goldman Sachs Group began coverage on Natera in a research note on Friday, June 5th. They issued a "neutral" rating and a $245.00 price objective on the stock. Finally, Canaccord Genuity Group set a $375.00 price objective on Natera in a report on Friday, August 7th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $319.38.

Insider Buying and Selling

In other Natera news, Director Gail Boxer Marcus sold 11,000 shares of the business's stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $217.21, for a total value of $2,389,310.00. Following the completion of the transaction, the director directly owned 6,183 shares in the company, valued at approximately $1,343,009.43. The trade was a 64.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Solomon Moshkevich sold 3,410 shares of the stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $265.58, for a total transaction of $905,627.80. Following the sale, the insider directly owned 129,019 shares of the company's stock, valued at approximately $34,264,866.02. The trade was a 2.57% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 177,955 shares of company stock valued at $40,704,193 over the last three months. Corporate insiders own 5.05% of the company's stock.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.